Pricing Log in Create free account
Saturday 17 October 2026 Export BSX’s income statement to Excel — free account

Boston Scientific Corporation

BSX Healthcare Medical Devices

Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024. In the quarter to June 2026, revenue grew 7.53%, EPS grew 14.8%, free cash flow grew 13.3% and total debt rose 8.95%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

44.39 0.25 +0.57%
Market cap
$64.0B
P/E
17.9×
Fwd P/E
17.8×
Dividend yield
—
F-score
7/9
Altman Z
5.41
Beneish M
−2.49
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Boston Scientific Corporation 10-K filed Feb 17, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 4:08 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business, against the 10-K filed Feb 18, 2025: 16 added · 131 removed · 36 modified; 1 with only figures updated; 1 moved without change

  1. Modified · Business Strategy

    We operate pursuant to five strategic imperatives. We aim to: Strengthen Category Leadership, Expand into High Growth Adjacencies, Drive Global Expansion, Fund the Journey to Fuel Growth and Develop Key Capabilities. We believe that our execution of these strategic imperatives will help us deliver on our mission, drive innovation and increase value for our customers and employees, while strengthening our leadership position in the medical device industry and delivering profitable revenue growth.

182 more changes in this Item, word by word, in Powerpack.

Powerpack